智通财经APP获悉，兆科眼科-B(06622)午后涨超8%，截至发稿，涨7.14%，报3.75港元，成交额1160.3万港元。
消息面上，兆科眼科发布中期业绩，该集团取得收益1580.3万元，同比减少68.25%；净亏损1.17亿元，同比增加53.85%。值得注意的是，2025年上半年兆科眼科硫酸阿托品滴眼液、环孢素眼用凝胶、贝伐单抗玻璃体注射液三款核心候选药物已进入新药申请（NDA）阶段，并且兆科眼科预计在2026年底前实现累计12款药物商业化的重要目标。
兆科眼科此前宣布，公司已与印尼领先制药公司PT Ferron Par Pharmaceuticals，就公司之核心产品：用于减缓儿童和青少年近视进展的硫酸阿托品滴眼液(NVK002)，签订了一份针对印尼市场的分销和供应协议。根据协议条款，兆科眼科授予PT Ferron在印度尼西亚进口、推广、分销、营销和销售该产品的独家权利。兆科眼科将获得一笔预付款项，并可根据若干成就获得额外的里程碑付款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.